Rasilez - About Hypertension

ZURICH, Dec 20 - Swiss drugmaker Novartis said it was ending a study of a drug to treat high blood pressure after an independent body said it could increase risk to patients with a high risk of heart or kidney problems.Novartis said ...

Results from 3A Registry demonstrate significant systolic blood pressure lowering with Rasilez after one year. ? After one year of treatment, Rasilez - the only approved direct renin inhibitor (DRI) - provided better systolic blood pressure control than other treatment regimens1. Results ...

Updated European Society of Hypertension (ESH) guidelines recognize that Rasilez? monotherapy is effective at lowering blood pressure in a single daily dose1. The updated European Guidelines on Hypertension Management, appraised by an ESH task force, recognize that Rasilez effectively lowers high blood ...

The US Food and Drug Administration (FDA) has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood ...

New AGELESS data show Rasilez lowers systolic blood pressure by additional 2.3 mmHg in patients aged 65 and over compared to ACE inhibitor ramipril1. . AGELESS, part of the ASPIRE HIGHER clinical program, is the third study to show Rasilez provides a ...

Data presented at European Society of Cardiology congress confirmRasilez is effective in difficult-to-treat patients with obesity, heart failure and diabetes[1],[2],[3]. * Data from ALOFT study shows Rasilez reduces marker of heart failure severity when added to optimal therapy in chronic heart failure ...

Novartis and Speedel have a long-standing collaboration based on financial support for Speedel creation in 1998 and development of Tekturna/Rasilez * Speedel pipeline provides access to many R&D projects targeting cardiovascular disease, including a range of direct renin inhibitors * Ownership of ...

Topic: Rasilez

Novartis ends study of drug in high risk patients

Results from 3A Registry demonstrate significant systolic blood pressure lowering with Rasilez after one year

Updated European guidelines highlight benefits of Rasilez, the only approved direct renin inhibitor, in treating high blood pressure

Novartis receives FDA approval for Valturna, a single-pill combination of valsartan and aliskiren, to treat high blood pressure

Rasilez, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older

Rasilez , First-in-Class Direct Renin Inhibitor, Lowers High Blood Pressure More Effectively Than Diuretic in Obese Patients

Novartis Buys Additional 51.7% Stake in Speedel and Announces Plans to Acquire Remaining Shares in a Mandatory Public Tender Offer

From Around the Web

Video Gallery

Follow this Topic with...